Pharmaceutical Technology-11-02-2011

Small drug companies with hopes of achieving $1 billion in sales can pursue various strategies.

Clamor mounts over compromised care and rising costs due to lack of crucial therapies.

Pharmaceutical companies are responding to the high cost of introducing new drugs to market in different ways.

Careful mixing during a product's distillation can help avert trouble from a strong concoction.

Researchers develop various catalytic approaches for improving yield, purity, stereoselectivity, and process conditions.

British racing car company and GlaxoSmithKline team up on a winning formula for innovation.

Novartis AG and Novartis Pharmaceuticals Corporation have been focusing research efforts on rare diseases since the company was established in 1996.

Pharma companies and their suppliers are tasked with managing an evermore complex clinical-trial material supply chain.

New product reviews for November 2011.

Biosimilar manufacturers need better expression systems and analytical tools to compete.

The study evaluates near-infrared analysis of tablets nominally containing 4 mg of chlorpheniramine maleate and 10 mg of phenylephrine hydrochloride per dose.

The authors describe the operational qualification of test accuracy with regard to temperature drift using a thermal-compensation algorithm on several freeze dryers.

At a time when the industry is struggling with innovation, it might do well to learn a lesson from a few great innovators.

The fifth in a series of eight case studies from the Product Quality Research Institute focuses on nonsterile facility cleaning requirements.

Russia is aiming to provide an alternative to China and India for drug manufacturing, including APIs.

The authors propose a plan to keep the US pharma industry afloat and in the lead.

Click the title above to open the Pharmaceutical Technology November 2011 issue in an interactive PDF format.